Research
White paper supports Sequel progressive addition lenses for digital eye strain
After 6 weeks, patients experienced an average of 71% reduction in DES symptoms and three-fourths reported no end-of-day fatigue.
Products
Remidio's portable fundus camera offers point-of-care imaging
FDA-cleared and smartphone-based diagnostic device offers complete imaging for both eyes in less than 1 minute—across a wide range of clinical settings.
Pipeline
Preliminary data evaluates Astellas's RPE cell therapy for advanced GA
Presented at ARVO 2026, early 26- and 52-week safety phase 1b data from highlights notable visual gains in patients receiving ASP7317.
Research
Oculis's global DME consensus study identifies critical gaps in care
Expert panel highlights disease management while emphasizing the importance of early intervention and non-invasive treatment options based on BCVA outcomes.
Products
Cellution Biologics debuts ocular surface amniotic graft
Introduced at ASCRS 2026, OptiCover is designed for in-office ophthalmic use as a protective covering on the ocular surface.
Products
FDA clears Balance Ophthalmics' wireless-enabled IOP device for glaucoma
Next-generation iteration of the portable IOP-lowering system delivers patient usage data to clinical practices from nighttime monitoring.
Research
Do anti-VEGF injections increase cataract risk?
A 15-year retrospective study found injected eyes nearly six times more likely to undergo cataract surgery than their untreated fellow eyes.
Research
Real-world TED data finds disease advances beyond acute phase
Real-world study demonstrates heterogeneous disease progression in TED, challenging the traditional self-limited paradigm.
Pipeline
FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial
Agreement on the PIONEER-1 study offers regulatory alignment on privosegtor’s registration path as a potential neuroprotective candidate.
Products
CooperVision launches new 180-pack for MyDay Energys daily contact lens
First introduced in 2023, this is the only 1‑day lens with a single-vision aspheric design and material technology to help eye tiredness and dryness linked to digital device use.
Pipeline
Atsena releases positive XLRS interim data from LIGHTHOUSE study
Enrollment for Part C of the study is underway, with the company targeting a 2028 BLA submission for ATSN-201, an investigational gene therapy.
Events
ARVO 2026 signals a turning point for retina innovations
Highlights from this year’s research in vision and ophthalmology meeting covered genetics, gene editing, AI, advanced imaging, and more.
Products
IDOC introduces new Clerra ophthalmic lens range
First product under the IDOC Labs portfolio streamlines the lens selection process while covering 90% of dispensing needs, cutting lab costs by 25%, and boosting capture rates.
Events
Registration opens for Eyes On Glaucoma 2026
The largest virtual glaucoma event of the year offers up to 5 hours of free CE from leading clinical experts in the industry.
Business
Bayer to acquire Perfuse Therapeutics, expanding ophthalmic pipeline
Deal includes the biotech’s investigational sustained-release implant currently in phase 2 clinical trials for glaucoma and diabetic retinopathy.
Pipeline
New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression
Unveiled at ARVO 2026, DOT lenses saved more than 1 D of myopic progression on average after 2 years among 6-to-10-year-old wearers.
Research
Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression
Latest 12-month data details highest myopia-control efficacy results reported to date in myopes as young as age 4 wearing HOYA’s D.I.M.S. technology.
Events
B+L Vision Care Summit spotlights contact lens and technology advancements
Clinicians share insights on dry eye care, contact lens adoption, and patient-centered treatment approaches.
Research
Are blue-light blocking IOLs actually effective?
Yellow-tinted lenses were associated with a decline in macular pigment density over 3 years, the opposite of the intended effect.
Business